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months in the empiric treatment of neutropenic fever: imipenem
monotherapy, cefepime plus tobramycin (extended-interval dos-
ing), and piperacillin/tazobactam plus tobramycin (extended-inter-
val dosing). Levoﬂoxacin was initiated as prophylaxis in March
2002 if the duration of neutropenia was expected to be  10 days.
For the time periods before (January 1999 to December 2001) and
after (January 2002 to June 2004) the initiation of antibiotic cycling
and levoﬂoxacin prophylaxis, we retrospectively compared the rates
of bacteremia (excluding coagulase-negative staphylococcus) and
antimicrobial use. Results: The rate of gram-positive bacteremia
was similar in the 2 periods (4.6 vs 4.8 episodes/1000 patient days;
P .87). However, there was an emergence of methicillin-resistant
Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and
levoﬂoxacin-resistant Streptococcus species during the period of anti-
biotic rotation and prophylaxis. Gram-negative bacteremia rates
decreased signiﬁcantly (4.8 vs 1.8 episodes/1000 patient days; P 
.003), and Klebsiella species disappeared from culture isolates. After
the initiation of antibiotic cycling, the rates of Pseudomonas isolates
decreased (1.7 vs 0.7 episodes/1000 patient days; P  .09), and
isolated strains were less resistant to ceftazidime and piperacillin.
Vancomycin use decreased during the period of antibiotic cycling
and prophylaxis (397 vs 289 deﬁned daily dose/1000 patient days;
P  .001). Conclusions: The introduction of antibiotic cycling
and prophylaxis in our BMT unit was associated with a signiﬁcant
decrease in gram-negative bacteremia rates. Although there was no
evidence of emerging resistance among the gram-negative isolates,
there was an increased rate of MRSA and VRE bacteremia.
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SINGLE CENTER EXPERIENCE WITH COLLECTION AND ADMINISTRA-
TION OF G-CSF–MOBILIZED, IRRADIATED GRANULOCYTE TRANSFU-
SIONS FROM DIRECTED DONORS TO SUPPORT PATIENTS AT HIGH
RISK FOR INFECTIONS UNDERGOING UNRELATED DONOR BLOOD AND
MARROW TRANSPLANTATION
Allison, J., Stephens, C., Waters-Pick, B., Bradshaw, T., Whitlock, P.,
Kurtzberg, J. Duke University Medical Center, Durham, NC.
Over the past 7.5 years, we supported patients at increased risk
for infection for 4–10 weeks posttransplantation with G-CSF
primed, irradiated granulocyte transfusions (grans) harvested from
a healthy family member. After clearance and placement of a
central venous catheter, donors were injected with G-CSF (10
g/kg) 12–15 hours before donation, twice weekly, 3 days apart.
Grans were collected on a Baxter CS3000 blood separator, irra-
diated, and divided into 3 equal aliquots to be administered on the
day of collection and the next 2 days. RBC and plasma were
depleted as needed to prevent reactions due to ABO incompatibil-
ity between the patient, their transplantation donor, and the gran-
ulocyte donor. Grans were stored at 4°C on a blood rotator until
warming to room temperature before infusion. Each collection was
tested for cell count, viability, bacterial and fungal cultures. After
premedication with antihistamines and steroids, the grans were
infused into the patient over 2 hours daily for 6–7 days per week.
Patients did not receive more than 5  108 cells/kg during a single
infusion. Donors were supported with iron, vitamin K, and cal-
cium. A total of 82 patients (32 with fungal infections, 26 under-
going second transplant, 22 with other infections, and 2 with
surgical wounds) received 2800 granulocyte transfusions from 91
donors harvested in 939 separate donation procedures. The aver-
age number of donations per donor was 10 over 5 weeks. The
average WBC in donors before collection was 42.17  106/L
(range, 3.49–87.9). The median number of grans collected at each
procedure was 5.71  1010 total cells (range, 0.025–21.7), with a
viability of  98%. Some 6% of the collections were discarded
before infusion due to bacterial contamination (3%) or clotting
(3%). Donor complications included line infection in 14% of
donors requiring CVL removal in 5%, pruritis in 2.5%, and hy-
poproteinemia in 1%. The mean drop in donor hemoglobin be-
tween the ﬁrst and last procedure was 2 g. There were no serious
complications in gran recipients. Less than 10% of patients with
active infections experienced progression or recurrence of infec-
tion on granulocyte support. We conclude that patients with in-
vasive fungal disease, prolonged neutropenia, and surgical wounds
can be maintained infection-free during marrow aplasia after allo-
geneic stem cell transplantation with regular transfusions of irra-
diated granulocytes. Risks to donors are minimal despite repeated
donations over 1–2 months.
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SAFETY OF BISPHOSPHONATE USE IN HEMATOPOIETIC PROGENITOR
CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS
Mazj, S., Ng, N., Lichtman, S.M., John, V., Devoe, C., Bayer, R.-L.
North Shore University Hospital, Manhasset, NY.
Background: The clinical course of multiple myeloma is often
associated with signiﬁcant bone disease. Bisphosphonates have
been shown to reduce the number of skeletal events. Treatment is
continued even after hematopoietic progenitor cell transplant.
Studies have shown renal toxicity associated with different bisphos-
phonates.Methods:We retrospectively reviewed the records of all
multiple myeloma patients who underwent hematopoietic progen-
itor cell transplantation and received bisphosphonates during the
period January 2001 to June 2004 at our institution. A total of 22
patients were analyzed. The types of bisphosphonates used were
zolendronate and pamidronate. Patients were categorized as to the
type of bisphosphonate used and age. Renal dysfunction was de-
ﬁned as an increase in serum creatinine of  0.5 mg/dL over
baseline. Results: Five of the 22 patients (22.7%) developed renal
dysfunction. The table shows the distribution of patients, type of
bisphosphonate, and the distribution of patients with renal toxicity.
Among the 5 patients who developed renal impairment, 4 patients
(80%) completely recovered their renal function and continued to
use bisphosphonates. Conclusions: The analysis shows that
bisphosphonates can be safeley used in multiple myeloma patients
who have undergone hematopoietic progenitor cell transplant. If
renal dysfunction develops during treatment, then the bisphospho-
nate can be discontinued temporarily. Renal function is likely to
recover, and the bisphosphonate can be safely reimplemented.
Table 1. All Patients Who Received Bisphosphonates by Type and Age
(1/2001–6/2004)
Age Group Zometa Aredia Zometa and Aredia Total
30–39 0 0 0 0
40–49 4 0 2 6
50–59 4 1 1 6
60–69 5 3 1 9
70–79 0 0 1 1
80 0 0 0 0
Total 0 0 0 22
Renal Impairment by Age and Type of Bisphosphonate in
Transplanted Multiple Myeloma Patients
30–39 0 0 0 0
40–49 1 0 1 2
50–59 0 0 0 0
60–69 0 2 0 2
70–79 0 0 1 1
80 0 0 0 0
Total 1 2 2 5
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VALGANCICLOVIR FOR THE PROPHYLAXIS OF EARLY CYTOMEGALOVIRUS
(CMV) INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Bachier, C.1, Shaughnessy, P.1, Wall, D.1, Grimley, M.1, Carrum, G.2,
Freytes, C.3, Callander, N.3, Walsh, T.3, LeMaistre, C.F.1 1Texas
Transplant Institute, San Antonio, TX; 2Center for Cellular and Gene
Therapy, Houston, TX; 3University of Texas Health Science Center, San
Antonio, TX.
The use of highly immunosuppressive therapies prior to and after
transplantation and the use of matched unrelated (MUD) and
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